4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2019 by 4BIO Ventures Management Ltd

NEWS ROOM

February 25, 2019

Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion. Spark Therapeutics will continue its oper...

February 22, 2019

Orchard Therapeutics plc (Nasdaq:ORTX) presents Two-Year Follow-Up Data versus historical control from Registrational Trial of OTL-101 for the Treatme...

November 1, 2018

Orchard Therapeutics plc (Nasdaq:ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening...

August 13, 2018

Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene th...

April 13, 2018

GlaxoSmithKline (GSK) said today it will hand off its rare disease gene therapy portfolio — including its European-approved gene therapy Strimvelis™ —...

March 24, 2018

TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) and Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the E...

January 5, 2018

TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory proper...

January 3, 2018

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announc...

December 19, 2017

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced tod...

Please reload

ARCHIVE
Please reload

SEARCH BY TAGS
Please reload

FOLLOW US